• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱表浅癌:自然病程及干扰素的作用

Superficial carcinoma of the bladder: natural history and the role of interferons.

作者信息

Torti F M, Lum B L

出版信息

Semin Oncol. 1986 Sep;13(3 Suppl 2):57-60.

PMID:3532337
Abstract

Superficial transitional cell carcinoma of the bladder is a chronic disease. Patients face a lifetime with the potential for further neoplastic manifestations--the recurrence of either superficial or deeply invasive tumor. To some extent, the likelihood of disease recurrence can be predicted. Further, certain clinical interventions can alter the probability of tumor recurrence. This paper focuses on those patient and tumor characteristics that predict for the propensity to develop recurrent disease, with emphasis on the potential of the interferons to both treat this disease and to modify its natural history.

摘要

膀胱浅表性移行细胞癌是一种慢性疾病。患者一生都面临着进一步发生肿瘤表现的可能性——浅表或深部浸润性肿瘤的复发。在一定程度上,疾病复发的可能性是可以预测的。此外,某些临床干预措施可以改变肿瘤复发的概率。本文重点关注那些能够预测复发性疾病发生倾向的患者和肿瘤特征,重点探讨干扰素治疗这种疾病并改变其自然病程的潜力。

相似文献

1
Superficial carcinoma of the bladder: natural history and the role of interferons.膀胱表浅癌:自然病程及干扰素的作用
Semin Oncol. 1986 Sep;13(3 Suppl 2):57-60.
2
Superficial bladder cancer. Risk of recurrence and potential role for interferon therapy.浅表性膀胱癌。复发风险及干扰素治疗的潜在作用。
Cancer. 1987 Feb 1;59(3 Suppl):613-6. doi: 10.1002/1097-0142(19870201)59:3+<613::aid-cncr2820591307>3.0.co;2-3.
3
[Immunotherapy of urothelial neoplasms. Experimental and clinical implications of alpha interferon].
Arch Esp Urol. 1990;43 Suppl 2:149-58.
4
[Treatment and follow-up of superficial bladder cancer].[浅表性膀胱癌的治疗与随访]
Duodecim. 2002;118(9):903-9.
5
Flat intra-epithelial carcinoma in situ of the urinary bladder.膀胱原位扁平上皮内癌。
Scand J Urol Nephrol. 1985;19(4):253-5. doi: 10.3109/00365598509180265.
6
[Studies on multiple mucosal biopsy in patients with bladder cancer. 2. Evaluation on the relationship between the results of multiple mucosal biopsy and recurrence, and the clinical course of cases with carcinoma in situ and micro-invasion of carcinoma in situ].[膀胱癌患者多次黏膜活检的研究。2. 多次黏膜活检结果与复发之间关系的评估,以及原位癌和原位癌微浸润病例的临床病程]
Hinyokika Kiyo. 1986 Nov;32(11):1633-47.
7
Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.浅表性膀胱肿瘤患者的临床全尿路上皮疾病:治疗意义。
J Urol. 2002 May;167(5):2007-11.
8
Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.α干扰素治疗浅表性膀胱癌:北加利福尼亚肿瘤学组的研究
J Clin Oncol. 1988 Mar;6(3):476-83. doi: 10.1200/JCO.1988.6.3.476.
9
Intravesical therapy: does it affect the natural history of superficial bladder cancer?膀胱内灌注治疗:它会影响浅表性膀胱癌的自然病程吗?
Semin Urol. 1992 Feb;10(1):39-44.
10
The management of superficial bladder tumours.浅表性膀胱肿瘤的管理
Singapore Med J. 1987 Aug;28(4):304-7.

引用本文的文献

1
Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder.作为膀胱浅表移行细胞癌患者免疫功能障碍参数的外周血单个核细胞中Th1和Th2细胞因子的流式细胞术分析
Cancer Immunol Immunother. 2006 Jun;55(6):734-43. doi: 10.1007/s00262-005-0045-2. Epub 2005 Nov 10.
2
Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group.重组人干扰素-β膀胱内治疗膀胱癌。膀胱内GKT-β化疗研究组。
Cancer Immunol Immunother. 1989;30(2):81-5. doi: 10.1007/BF01665957.
3
Approaches to the treatment of bladder cancer at Stanford.
Cancer Chemother Pharmacol. 1987;20 Suppl:S63-6. doi: 10.1007/BF00262489.